Ipca Labs Q3 FY25 profit soars, boosted by formulations
** Ipca Laboratories Limited announced robust financial results for the third quarter and nine months ended December 31, 2024. Standalone net total income increased 10% to ₹1680.09 crores, while consolidated net total income rose 9% to ₹2265.48 crores. Indian formulations drove growth, increasing 13% to ₹877.17 crores, and exports grew by 6% to ₹680.91 crores. Standalone EBITDA margin improved significantly to 24.25%, up from 18.52% in Q3 FY24. Consolidated EBITDA margin also improved to 19.87%. Standalone net profit surged 95% to ₹267.56 crores, and consolidated net profit increased 38% to ₹248.14 crores. Basic earnings per share increased by 96% for Standalone (Re. 10.55) and 38% for consolidated (Re. 9.78). The company's consolidated nine-month revenue from operations reached ₹6692.90 crores, an 18% increase over the previous year, with a net profit after tax of ₹669.86 crores, up 37%.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
Supplementary Source Documents
News Alerts
Get instant email alerts when Ipca Laboratories publishes news
Free account required • Unsubscribe anytime